Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to ...

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed at ensuring its own PD-1 stalwart doesn’t miss out on the action. GSK, ...

Judge in Depo-Provera MDL Orders Additional Briefing on FDA's Brain Tumor Warning At a Friday hearing, U.S. District Judge M. Casey Rodgers, of the Northern District of Florida, ordered supplemental ...

If you took the warning label that comes with your birth control and tossed it right in the trash, you wouldn’t be alone. After all, every medication comes with a risk of side effects, and those ...

The U.S. Food and Drug Administration (FDA) approved a new safety warning for Depo-Provera, a widely used birth control shot made by Pfizer, alerting patients to a possible risk for a type of brain ...

The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...

The Food and Drug Administration approved on Friday a label change for Pfizer's birth control shot Depo-Provera that warns patients of the risk of meningioma, a tumor in the lining of the brain.

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...

Decades after receiving regular injections of the hormonal contraceptive Depo-Provera, an estimated 1,300 women are now suing manufacturer Pfizer, alleging the company failed to adequately warn users ...

WESTWEGO, La. — Robin Phillip’s fresh haircut is dyed her favorite color — green. But beneath the dye job is a scar that runs along the side of her head, the result of two craniotomies. For years, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...